BFLY-WT — Butterfly Network, Inc.

Butterfly Network Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $21.5 million, a 5% increase year-over-year, driven by higher average selling prices and increased volume, particularly in the U.S.
• U.S. Revenue: $16.1 million, slightly up from the prior year, supported by e-commerce and veterinary distribution.
• International Revenue: $5.4 million, up 4% year-over-year, primarily due to the international launch of the iQ3.
• Product Revenue: $14.6 million, an 8% increase from Q3 2024.
• Software and Services Revenue: $6.9 million, flat compared to the previous year.
• Gross Margin: Reported at -17.5%, impacted by a $17.4 million noncash inventory write-off; adjusted gross margin improved to 63.9%.
• Adjusted EBITDA Loss: $8.1 million, an improvement from $8.4 million in Q3 2024.
• Cash Position: $148 million in cash and equivalents at the end of the quarter, with a trailing 12-month cash burn of $31.5 million.

2. Strategic Updates and Business Highlights

• Enterprise Sales Strategy: Butterfly is focusing on building enterprise sales through a holistic approach in major medical institutions, despite facing headwinds from broader macroeconomic issues.
• AI Integration: The POCUS CARE trial published in JAMA highlighted significant clinical and economic benefits from Butterfly's AI tools, which are expected to enhance enterprise sales.
• Product Development: The upcoming launch of the next-gen enterprise software, Compass AI, is anticipated to improve hospital workflows.
• Education Initiatives: The launch of the HeartFocus app, which guides echo probe placement, aims to enhance accessibility and efficiency in cardiac scans.
• Global Expansion: Continued deployment of Butterfly devices in low- and middle-income countries, with over 1,000 devices in sub-Saharan Africa.

3. Forward Guidance and Outlook

• Revenue Guidance: Reaffirmed full-year revenue guidance of $91 million to $95 million, implying Q4 revenue of $25 million to $29 million.
• Adjusted EBITDA Loss Guidance: Tightened to a range of $32 million to $35 million for the full year, with Q4 losses expected between $9 million and $12 million.
• Pipeline Confidence: Management expressed optimism about closing large deals in the pipeline, particularly as the new budget cycle begins in 2026.

4. Bad News, Challenges, or Points of Concern

• Headwinds: Continued delays in purchase decisions from hospital customers due to macroeconomic factors, with a longer sales cycle noted.
• Inventory Write-Off: A significant noncash charge for excess inventory related to the previous generation of probes, reflecting a shift in demand towards the iQ3.
• Regulatory Risks: Potential impacts from the ongoing federal government shutdown, which could affect customer cash flow and regulatory processes, although not currently seen as a significant risk.
• Subscription Churn: Increased churn in individual subscriptions, although enterprise subscriptions have seen an uptick.

5. Notable Q&A Insights

• Sales Pipeline: Management noted that deals worth 100 to 200 probes have been delayed but emphasized that they are not losing deals, indicating strong underlying demand.
• Economic Evidence: The JAMA study's findings are expected to strengthen the economic argument for Butterfly's products in enterprise sales discussions.
• Home Care Program: Management remains optimistic about transitioning the home care pilot to a commercial agreement, although no specific updates were provided.
• AI Developments: The Apollo AI chip is expected to enhance local processing capabilities, which could significantly improve the performance and efficiency of Butterfly's devices.

Overall, Butterfly Network reported steady growth in Q3 2025, with strategic initiatives in AI and enterprise sales positioning the company for future success, despite facing some macroeconomic headwinds and challenges in subscription renewals.